cas 922178-61-8|| where to buy (R)-3-Methylpiperazin-2-one

Nombre del producto:(R)-3-Methylpiperazin-2-one

IUPAC Name:(3R)-3-methylpiperazin-2-one

Unidad de embalaje	Stock disponible	Precio($)
CM120132-100mg	in stock	ƃǑ
CM120132-250mg	in stock	ȖȅŞ
CM120132-1g	in stock	Ūƃƥ
CM120132-5g	in stock	ƛƃŞ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 922178-61-8 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :922178-61-8; Fórmula molecular:C5H10N2O; Punto de fusión:-; Código de sonrisas:O=C1NCCN[C@@H]1C; Densidad:

: Número de catálogo:CM120132; Peso molecular:114.15; Punto de ebullición:; Nº Mdl:MFCD07373460; Almacenamiento:Store at 2-8°C.

: Piperazines; Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

: Fezolinetant; Dec 10, 2023, VEOZA (fezolinetant) approved by European Commission for treatment of vasomotor symptoms associated with menopause.
VEOZAH is the first and only neurokinin 3 (NK3) receptor antagonist that blocks NKB from binding on KNDy neurons to help reduce heat signals that trigger VMS. First-in-class fezolinetant brings women a new nonhormonal therapy for hot flashes.
In May 2023, FDA has approved VEOZA(fezolinetant) 45 mg once daily for the treatment of moderate to severe VMS due to menopause.